The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study

Chin Hui Yang, Kuan Jung Chen, Jih Jin Tsai, Yu Hui Lin, Shu Hsing Cheng, Kwei Feng Wang, Hung Yi Chiou

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Optimal timing for initiating highly active antiretroviral therapy (HAART) in HIV-TB coinfected patients is challenging for clinicians. We aim to evaluate the impact of different timing of HAART initiation on TB outcome of HIV-infected adults in Taiwan.Methods: A population-based retrospective cohort study was conducted through linking the HIV and TB registries of Taiwan Centers for Disease Control (CDC) during 1997 to 2006. Clinical data of HIV-TB co-infected patients, including the presence of immune reconstitution inflammatory syndrome (IRIS), was collected through medical records review. The outcome of interest was all-cause mortality within 1 year following TB diagnosis. The Cox proportional hazard model was used to explore the probability of death and IRIS after TB diagnosis by adjusting for confounding factors and factors of interest. The probability of survival and TB IRIS were calculated by the Kaplan-Meier method and compared between different HAART initiation timing groups by the log-rank test.Results: There were 229 HIV-TB co-infected patients included for analysis and 60 cases (26.2%) died within one year. Besides decreasing age and increasing CD4 lymphocyte count, having started HAART during TB treatment was significantly associated with better survival (adjusted Hazard Ratio was 0.11, 95% CI 0.06-0.21). As to the timing of HAART initiation, there was only non-significant benefit on survival among cases initiating HAART within 15 days, at 16-30 days and at 31-60 days of TB treatment than initiating after 60 days. Cases with HAART initiated after 30 days had lower risk in developing IRIS than cases with HAART initiated earlier. Cases with IRIS had significantly higher rate of re-hospitalization (49% vs. 4%, p <0.001) and prolonged hospitalization (28 days vs. 18.5 days, p <0.01).Conclusion: The present study found that starting HAART during TB treatment is associated with better one-year survival, although earlier initiation within 60 days of TB treatment did not show statistical differences in survival than later initiation. Initiation of HAART within 30 days appeared to increase the risk of IRIS. Deferring HAART to 31-60 days of TB treatment might be optimal after considering the risks and benefits.

Original languageEnglish
Article number304
JournalBMC Infectious Diseases
Volume14
Issue number1
DOIs
Publication statusPublished - Jun 4 2014

Fingerprint

Highly Active Antiretroviral Therapy
Cohort Studies
Immune Reconstitution Inflammatory Syndrome
Retrospective Studies
HIV
Survival
Taiwan
Hospitalization
Therapeutics
Centers for Disease Control and Prevention (U.S.)
CD4 Lymphocyte Count
Proportional Hazards Models
Medical Records
Registries

Keywords

  • HAART
  • HIV
  • Mortality
  • Tuberculosis

ASJC Scopus subject areas

  • Infectious Diseases
  • Medicine(all)

Cite this

The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study. / Yang, Chin Hui; Chen, Kuan Jung; Tsai, Jih Jin; Lin, Yu Hui; Cheng, Shu Hsing; Wang, Kwei Feng; Chiou, Hung Yi.

In: BMC Infectious Diseases, Vol. 14, No. 1, 304, 04.06.2014.

Research output: Contribution to journalArticle

Yang, Chin Hui ; Chen, Kuan Jung ; Tsai, Jih Jin ; Lin, Yu Hui ; Cheng, Shu Hsing ; Wang, Kwei Feng ; Chiou, Hung Yi. / The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study. In: BMC Infectious Diseases. 2014 ; Vol. 14, No. 1.
@article{a9b40a9d56384928972e9d9df3f635ab,
title = "The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study",
abstract = "Background: Optimal timing for initiating highly active antiretroviral therapy (HAART) in HIV-TB coinfected patients is challenging for clinicians. We aim to evaluate the impact of different timing of HAART initiation on TB outcome of HIV-infected adults in Taiwan.Methods: A population-based retrospective cohort study was conducted through linking the HIV and TB registries of Taiwan Centers for Disease Control (CDC) during 1997 to 2006. Clinical data of HIV-TB co-infected patients, including the presence of immune reconstitution inflammatory syndrome (IRIS), was collected through medical records review. The outcome of interest was all-cause mortality within 1 year following TB diagnosis. The Cox proportional hazard model was used to explore the probability of death and IRIS after TB diagnosis by adjusting for confounding factors and factors of interest. The probability of survival and TB IRIS were calculated by the Kaplan-Meier method and compared between different HAART initiation timing groups by the log-rank test.Results: There were 229 HIV-TB co-infected patients included for analysis and 60 cases (26.2{\%}) died within one year. Besides decreasing age and increasing CD4 lymphocyte count, having started HAART during TB treatment was significantly associated with better survival (adjusted Hazard Ratio was 0.11, 95{\%} CI 0.06-0.21). As to the timing of HAART initiation, there was only non-significant benefit on survival among cases initiating HAART within 15 days, at 16-30 days and at 31-60 days of TB treatment than initiating after 60 days. Cases with HAART initiated after 30 days had lower risk in developing IRIS than cases with HAART initiated earlier. Cases with IRIS had significantly higher rate of re-hospitalization (49{\%} vs. 4{\%}, p <0.001) and prolonged hospitalization (28 days vs. 18.5 days, p <0.01).Conclusion: The present study found that starting HAART during TB treatment is associated with better one-year survival, although earlier initiation within 60 days of TB treatment did not show statistical differences in survival than later initiation. Initiation of HAART within 30 days appeared to increase the risk of IRIS. Deferring HAART to 31-60 days of TB treatment might be optimal after considering the risks and benefits.",
keywords = "HAART, HIV, Mortality, Tuberculosis",
author = "Yang, {Chin Hui} and Chen, {Kuan Jung} and Tsai, {Jih Jin} and Lin, {Yu Hui} and Cheng, {Shu Hsing} and Wang, {Kwei Feng} and Chiou, {Hung Yi}",
year = "2014",
month = "6",
day = "4",
doi = "10.1186/1471-2334-14-304",
language = "English",
volume = "14",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study

AU - Yang, Chin Hui

AU - Chen, Kuan Jung

AU - Tsai, Jih Jin

AU - Lin, Yu Hui

AU - Cheng, Shu Hsing

AU - Wang, Kwei Feng

AU - Chiou, Hung Yi

PY - 2014/6/4

Y1 - 2014/6/4

N2 - Background: Optimal timing for initiating highly active antiretroviral therapy (HAART) in HIV-TB coinfected patients is challenging for clinicians. We aim to evaluate the impact of different timing of HAART initiation on TB outcome of HIV-infected adults in Taiwan.Methods: A population-based retrospective cohort study was conducted through linking the HIV and TB registries of Taiwan Centers for Disease Control (CDC) during 1997 to 2006. Clinical data of HIV-TB co-infected patients, including the presence of immune reconstitution inflammatory syndrome (IRIS), was collected through medical records review. The outcome of interest was all-cause mortality within 1 year following TB diagnosis. The Cox proportional hazard model was used to explore the probability of death and IRIS after TB diagnosis by adjusting for confounding factors and factors of interest. The probability of survival and TB IRIS were calculated by the Kaplan-Meier method and compared between different HAART initiation timing groups by the log-rank test.Results: There were 229 HIV-TB co-infected patients included for analysis and 60 cases (26.2%) died within one year. Besides decreasing age and increasing CD4 lymphocyte count, having started HAART during TB treatment was significantly associated with better survival (adjusted Hazard Ratio was 0.11, 95% CI 0.06-0.21). As to the timing of HAART initiation, there was only non-significant benefit on survival among cases initiating HAART within 15 days, at 16-30 days and at 31-60 days of TB treatment than initiating after 60 days. Cases with HAART initiated after 30 days had lower risk in developing IRIS than cases with HAART initiated earlier. Cases with IRIS had significantly higher rate of re-hospitalization (49% vs. 4%, p <0.001) and prolonged hospitalization (28 days vs. 18.5 days, p <0.01).Conclusion: The present study found that starting HAART during TB treatment is associated with better one-year survival, although earlier initiation within 60 days of TB treatment did not show statistical differences in survival than later initiation. Initiation of HAART within 30 days appeared to increase the risk of IRIS. Deferring HAART to 31-60 days of TB treatment might be optimal after considering the risks and benefits.

AB - Background: Optimal timing for initiating highly active antiretroviral therapy (HAART) in HIV-TB coinfected patients is challenging for clinicians. We aim to evaluate the impact of different timing of HAART initiation on TB outcome of HIV-infected adults in Taiwan.Methods: A population-based retrospective cohort study was conducted through linking the HIV and TB registries of Taiwan Centers for Disease Control (CDC) during 1997 to 2006. Clinical data of HIV-TB co-infected patients, including the presence of immune reconstitution inflammatory syndrome (IRIS), was collected through medical records review. The outcome of interest was all-cause mortality within 1 year following TB diagnosis. The Cox proportional hazard model was used to explore the probability of death and IRIS after TB diagnosis by adjusting for confounding factors and factors of interest. The probability of survival and TB IRIS were calculated by the Kaplan-Meier method and compared between different HAART initiation timing groups by the log-rank test.Results: There were 229 HIV-TB co-infected patients included for analysis and 60 cases (26.2%) died within one year. Besides decreasing age and increasing CD4 lymphocyte count, having started HAART during TB treatment was significantly associated with better survival (adjusted Hazard Ratio was 0.11, 95% CI 0.06-0.21). As to the timing of HAART initiation, there was only non-significant benefit on survival among cases initiating HAART within 15 days, at 16-30 days and at 31-60 days of TB treatment than initiating after 60 days. Cases with HAART initiated after 30 days had lower risk in developing IRIS than cases with HAART initiated earlier. Cases with IRIS had significantly higher rate of re-hospitalization (49% vs. 4%, p <0.001) and prolonged hospitalization (28 days vs. 18.5 days, p <0.01).Conclusion: The present study found that starting HAART during TB treatment is associated with better one-year survival, although earlier initiation within 60 days of TB treatment did not show statistical differences in survival than later initiation. Initiation of HAART within 30 days appeared to increase the risk of IRIS. Deferring HAART to 31-60 days of TB treatment might be optimal after considering the risks and benefits.

KW - HAART

KW - HIV

KW - Mortality

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84902539479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902539479&partnerID=8YFLogxK

U2 - 10.1186/1471-2334-14-304

DO - 10.1186/1471-2334-14-304

M3 - Article

C2 - 24897928

AN - SCOPUS:84902539479

VL - 14

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 304

ER -